Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia

Cytometry Part B - Clinical Cytometry

Volumn 70, Issue 4, 2006, Pages 214-217

  Bosch, Francesc ^a   Muntañola, Ana ^a   Giné, Eva ^a   Carrió, Ana ^a   Villamor, Neus ^a   Moreno, Carolina ^a   Crespo, Marta ^a   Montserrat, Emili ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Biological markers; Chronic lymphocytic leukemia; Prognosis

Indexed keywords

BIOLOGICAL MARKER; PROTEIN KINASE ZAP 70;

B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DISEASE COURSE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 33748486742     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20131     Document Type: Review

References (41)

1. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
3. Rozman C, Bosch F, Montserrat E. Chronic lymphocytic leukemia: A changing natural history? Leukemia 1997;11:775-778.
4. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica 2001;86:8-12.
5. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: Clinical, therapeutic, and prognostic features. Blood 2000;95:2788-2792.
6. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003;74:1-8.
7. Montserrat E. Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of century after Rai and Binet staging systems. Ann Oncol 2004;15:450-451.
8. Zent CS, Kay NE. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep 2004;5:348-354.
9. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
10. Döhner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: Reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77:266-281.
11. Cuneo A, Rigolin GM, Bigoni R, et al. Chronic lymphocytic leukemia with 6q- shows distinct haematological features and intermediate prognosis. Leukemia 2004;18:476-483.
12. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: Analysis of the antibody repertoire. Immunol Today 1994;15:288-294.
13. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
14. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
15. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and prognosis in chronic lymphocytic leukemia. Blood 2002;100:1410-1416.
16. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006;107:2889-2894.
17. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: The lesson of the IGHV3-21 gene. Blood 2005;105:1678-1685.
18. Hamblin TJ, Orchad JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029.
19. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647.
20. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
21. Carreras J, Villamor N, Colomo L, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005;205:507-513.
22. Catherwood MA, Matthews C, Niblock R, Dobbin E, Morris TC, Denis Alexander H. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur J Haematol 2006;76:294-298.
23. Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:3584-3592.
24. Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006;17:683-690.
25. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-111.
26. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
27. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-975.
28. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Steuer-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
29. Laurenti L, Petlickovski A, Rumi C, Gobessi S, Piccioni P, Tarnani M, Puggioni P, Marietti S, Sica S, Leone G, Efremov DG. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica 2005;90:1533-1540.
30. Bosch F, Crespo M, Villamor N, Muntañola A, Ferrer A, Domingo A, Rozman M, Rozman C, López-Guillermo A, Montserrat E. Clinical characteristics and outcome of a large series of patients with chronic lymphocytic leukaemia (CLL) according to ZAP-70 expression. Blood 2004;104:14; (ASH Annual Meeting Abstracts).
31. Shustik C, Turner R, Desjardins P, et al. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Phase II study of oral fludarabine in untreated B-cell chronic lymphocytic leukemia. Blood 2005;106:835a [abstract 2977].
32. Oscier DG, Richards S, Orchard J, et al. Prognostic factors in the UK LRF CLL4 trial. Blood 2005;106:594a [abstract 2099].
33. Stilgenbauer S, Krober A, Busch R, et al. 17p deletion predicts for inferior overall survival after fludarabine - based first line therapy in chronic lymphocytic leukemia: First analysis of genetics in the CLL4 trial of the GCLLSG. Blood 2005;106:212a [abstract 715].
34. Giraldo P, Rubio-Martinez A, Recasens V, et al. Genetic aberrations and response to fludarabine as first line treatment in a serie of B-CLL patients. Blood 2005;106:603a [abstract 2131].
35. Acs P, Mavromatis B, Ozdemirly M, et al. A prognostic model using ZAP-70, CD38 and cytogenetics to better predict need for early therapy and response to treatment in chronic lymphocytic leukemia (CLL). Blood 2005;106:598a [abstract 2114].
36. Khouri IF, Saliba RM, Keating MJ, et al. ZAP-70 status may not predict outcome after non-myeloablative allogeneic transplantation (NMT) in patients with chronic lymphocytic leukemia(CLL) who failed conventional chemotherapy. Blood 2005;106:577a [abstract 2114].
37. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006;24:437-443.
38. Heintel D, Kroemer E, Kienle D, et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IgVH gene status and unfavorable cytogenetic aberrations in patients with chronic lymphocytic leukemia. Leukemia 2004;4:756-762.
39. Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106:650-657.
40. Heintel D, Kienle D, Shehata M, et al. High expression of lipoprotein lipase in poor-risk B-cell chronic lymphocytic leukemia. Leukemia 2005;19:12l6-1223.
41. Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005;105:2036-2041.